<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676013</url>
  </required_header>
  <id_info>
    <org_study_id>97-286</org_study_id>
    <nct_id>NCT00676013</nct_id>
  </id_info>
  <brief_title>Comparison of Skin Substitutes Used in Burn Care</brief_title>
  <acronym>Quad</acronym>
  <official_title>The Use of Alloderm and Other Skin Substitutes in Acute Burn Treatment and Burn Scar Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if using a DERMAL LAYER under skin grafts:

        1. will reduce scar formation of skin grafts

        2. will reduce burn wound contractures

        3. will improve functional outcome of joints requiring grafts

      Compare scarring outcome of Dermal products
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Various skin substitutes are compared for healing, scar and functional and cosmetic outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to continue study following Hurricane Ike.
  </why_stopped>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Burn Scar Comparison</measure>
    <time_frame>2 years post burn injury</time_frame>
    <description>Burn scar is measured scar using the Vancouver Scar Scale (range 0-12) for each of the various skin substitutes used in grafting. Vancouver Scar Scale measure burn scarring assessing categories of redness/vascularity, hardness, pigmentation and scar height. Each item has a scale of 0-3. Score for each category is summed together for a total score between 0-12. The total score is generally used in the burn community, therefore the total score will be reported. Lower scores are better; higher scores are worse.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Alloderm, Integra, Homograft, Autograft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Integra</intervention_name>
    <description>Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.</description>
    <arm_group_label>Alloderm, Integra, Homograft, Autograft</arm_group_label>
    <other_name>Artificial dermis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AlloDerm</intervention_name>
    <description>Grafting using the commercial product AlloDerm as a skin substitute</description>
    <arm_group_label>Alloderm, Integra, Homograft, Autograft</arm_group_label>
    <other_name>Cadaver skin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Homograft</intervention_name>
    <description>Grafting using homograft as a skin substitute</description>
    <arm_group_label>Alloderm, Integra, Homograft, Autograft</arm_group_label>
    <other_name>Cadaver Skin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autograft</intervention_name>
    <description>grafting using patients own skin from a separate donor site</description>
    <arm_group_label>Alloderm, Integra, Homograft, Autograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn injury requiring grafting

          -  0 years-90 years

        Exclusion Criteria:

          -  Partial thickness burns only
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch, Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>August 6, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2019</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burns</keyword>
  <keyword>Skin grafting</keyword>
  <keyword>AlloDerm</keyword>
  <keyword>Integra</keyword>
  <keyword>Homograft</keyword>
  <keyword>Autograft</keyword>
  <keyword>Burn Scar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the Galveston Burn Unit following an acute burn injury that were diagnosed with 3rd degree burns. Study was active between 1997-2011.</recruitment_details>
      <pre_assignment_details>Patients were enrolled before their surgical procedure. After consent was obtained. After the surgical site was identified, the site was randomized to receive the various skin products.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alloderm, Integra, Homograft, Autograft</title>
          <description>Grafting with alloderm, Integra, Homograft, and/or Autograft on each patient. Different sites were then compared.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alloderm, Integra, Homograft, and/or Autograft</title>
          <description>Grafting with alloderm, integra, homograft and/or autograft. Various treatment sites were then compared.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Burn Scar Comparison</title>
        <description>Burn scar is measured scar using the Vancouver Scar Scale (range 0-12) for each of the various skin substitutes used in grafting. Vancouver Scar Scale measure burn scarring assessing categories of redness/vascularity, hardness, pigmentation and scar height. Each item has a scale of 0-3. Score for each category is summed together for a total score between 0-12. The total score is generally used in the burn community, therefore the total score will be reported. Lower scores are better; higher scores are worse.</description>
        <time_frame>2 years post burn injury</time_frame>
        <population>Each site grafted with a skin substitute was analyzed with a Scar Assessment</population>
        <group_list>
          <group group_id="O1">
            <title>AlloDerm</title>
            <description>Surgery using alloDerm. Various treatment sites were then compared.</description>
          </group>
          <group group_id="O2">
            <title>Integra</title>
            <description>Surgery with Integra grafting followed with autografting</description>
          </group>
          <group group_id="O3">
            <title>Homograft</title>
            <description>Surgery using Homograft followed with autografting</description>
          </group>
          <group group_id="O4">
            <title>Autograft</title>
            <description>Surgery with Autografting</description>
          </group>
        </group_list>
        <measure>
          <title>Burn Scar Comparison</title>
          <description>Burn scar is measured scar using the Vancouver Scar Scale (range 0-12) for each of the various skin substitutes used in grafting. Vancouver Scar Scale measure burn scarring assessing categories of redness/vascularity, hardness, pigmentation and scar height. Each item has a scale of 0-3. Score for each category is summed together for a total score between 0-12. The total score is generally used in the burn community, therefore the total score will be reported. Lower scores are better; higher scores are worse.</description>
          <population>Each site grafted with a skin substitute was analyzed with a Scar Assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scar Score 6 months post burn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="1.0"/>
                    <measurement group_id="O2" value="6.9" spread="1.4"/>
                    <measurement group_id="O3" value="12.0" spread="1.8"/>
                    <measurement group_id="O4" value="11.6" spread=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scar Score 24 months post burn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread=".9"/>
                    <measurement group_id="O2" value="4.7" spread=".8"/>
                    <measurement group_id="O3" value="4.8" spread=".7"/>
                    <measurement group_id="O4" value="5.6" spread=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>We conducted a multiple four group comparison (all pairwise comparisons were conducted). An Anova was conducted to assess statistical significance.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA and all pairwise comparisons using Tukey test.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>0.05 is a threshold for statistical significance.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Multiple pairwise comparisons</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>0.05</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1997-2011</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AlloDerm, Integra, Homograft, Autograft</title>
          <description>Skin product used on each of the four test sites on each patient</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>2001 Patient on insulin drip, glucose decreased to 35. Glucose treated,Insulin stopped. PI opinion:not related to study. 2001: Patient on insulin drip. Glucose decreased to 30. Patient treated, insulin stopped. PI opinion:not related to study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Invasive infection and death</sub_title>
                <description>2001: 74% burn admitted with invasive infection. Developed multi organ failure,, coded and expired. Patient never started study. PI stated Adverse Event not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Invasive infection, Multi organ failure, death</sub_title>
                <description>2001: 85% burn patient admitted with invasive infection. Developed sepsis, renal failure, multi organ failure. Patient allowed to die.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>90% burn admitted with renal failure, died</sub_title>
                <description>2001: 90% burn admitted with renal failure. After most of burns were grafted, renal failure worsened, patient eventually died. PI stated unlikely related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration and Death</sub_title>
                <description>2001: Following discharge from hospital, patient aspirated while sleeping. Advanced Cardiac Life Support provided however patient expired. PI felt Adverse Event not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Respiratory status compromised</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>2001: Chest tube pulled out. PI stated not related to study. 2001: Plugged Endotracheal tube x2. Endotracheal Tube pulled and replaced. PI opinion is Adverse Event is not related to study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>leg ischemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>2001: Arterial line placed for surgical procedure, right leg became ischemic. Treated with anticoagulants. No long term complications. PI stated not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall and open wound</sub_title>
                <description>2001: Patient fell trying to push chair and ripped skin open.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>2003: Hematoma following femoral IV line placement. PI opinion is Adverse Event is not related to study. 2006: hematoma developed following femoral IV line placement. PI opinion is Adverse Event is not related to study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Herndon, MD</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-770-6731</phone>
      <email>dherndon@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

